Navigation Links
MaxCyte Presents a Panel Discussion With Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery - LIVE Q&A to Follow

GAITHERSBURG, Md., Dec. 15 /PRNewswire/ --MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, announces that, due to popular demand, it will be rebroadcasting its webinar with industry experts on the challenges in developing cell-based screening assays for drug discovery. The broadcast is open to the industry and will be held by webinar on Tuesday December 16th at two convenient times, 9:00 AM and 7:30 PM EST. A live Q&A will follow the broadcast.

One of the respected industry experts who led the discussion was Dr. John Reardon, formerly Senior Vice President of Discovery Research Biology at Glaxo Smith Kline and now Executive Vice President and Chief Scientific Officer at Integrated Oncology Solutions Inc. (IOS) in North Carolina. Dr. Reardon reviewed the complexities of cell transfection technologies and challenged the webinar participants to consider the possibilities of creating more relevant assays if it were possible to transfect any molecule into any cell at any scale, while maintaining biological integrity and high quality standards. His discussion offered compelling arguments as to how the MaxCyte(R) STX System can reduce bottlenecks and improve the productivity of drug discovery groups.

Dr. James Brady, Director of Technical Applications at MaxCyte, led the webinar participants through a technical presentation of the MaxCyte(R) STX(TM) Scalable Transfection System. Dr. Brady demonstrated how the MaxCyte STX technology enables the large scale transfection of primary cells, cell lines, and stem cells with single and multiple loading agents at the same time, resulting in more relevant screening systems.

According to MaxCyte CEO Doug Doerfler, "We were delighted with the response to our previous webinar on the MaxCyte STX technology and the interest in continuing with the live panel discussion. The MaxCyte STX is being viewed by the pharmaceutical industry as an enabling technology for cell modification for both research and larger scale cell-based applications in drug discovery. The MaxCyte STX can produce billions of transfected cells in minutes compared to current time-consuming and inconsistent methods. This is possible even for large scale transfection of primary cell lines. More assays can be developed and performed in a shorter period of time, increasing the likelihood of finding a successful drug candidate."

To register for the free webinar, visit and click on the registration link. MaxCyte scientists will be available after the webinar to answer any technical questions relative to the performance and operation of the MaxCyte STX Scalable Transfection System. A recording of the webinar will be available on the MaxCyte website after the event.

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. The MaxCyte transfection technology was originally developed as an enabling technology for cell therapy and is currently being used in a number of clinical trials around the world. Drawing upon this expertise in cell loading for cell therapy, MaxCyte introduced this transfection technology into drug discovery applications as the MaxCyte(R) STX(TM) Scalable Transfection System. The MaxCyte STX allows for the rapid, scalable, and reagent-free cell transfection for cell based assays, preclinical protein production, and other cell-based applications.

For more information,

SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
2. MaxCyte to Present at the BIO CEO & Investor Conference
3. MaxCyte to Present at the Phacilitate Cell and Gene Therapy Forum 2008
4. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
5. Medicsight PLC Presents New Data at RSNA 2008 Further Supporting Relevance of Computer-Aided Detection (CAD) and Image Analysis Software in Early Colon Cancer Screening and Diagnosis
6. CVS Caremark Presents Influenza Vaccine Data at Rescheduled 2008 DMAA Annual Meeting
7. Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile
8. Sonic Innovations Presents Donation to the Armed Forces Foundation
9. HMS Presents 4th Annual Heroes of Healthcare Awards
10. HealthEdge(R) Presents Award-Winning HealthRules(R) Technology Platform at the 2008 Gartner Healthcare Summit
11. Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers
Post Your Comments:
(Date:11/29/2015)... ... November 29, 2015 , ... ... analog distortion effect tool designed specially for Final Cut Pro X. FCPX ... looks with the easy-to-use modification controls. Destoying and creating chaotic distortion is now ...
(Date:11/29/2015)... ... ... Effective immediately, every single IguanaMed scrub style will be available at Target ... a “Buy One Scrub Set, Get the 2nd Scrub Set 50% Off” for a ... discounted price. , IguanaMed’s mission is to outfit every healer around the ...
(Date:11/29/2015)... ... November 29, 2015 , ... Key Housing, a top-rated corporate housing ... December, 2015, featured apartment community: Epic. In showcasing this featured apartment community in San ... Bay Area rental market to efficiently find housing suitable to their needs by showcasing ...
(Date:11/28/2015)... San Diego, California (PRWEB) , ... November 28, ... ... cloud-based medical image exchange technology and teleradiology services, has added Chris Hafey and ... prepares to exhibit at the Radiological Society of North America (RSNA) 2015 Annual ...
(Date:11/28/2015)... ... ... Safe storage for contraceptive devices may not always be easy to find. However, ... other from Bradley Beach, New Jersey, there is an easy solution to the problem. ... NuvaRings more often than necessary. As such, it affords peace of mind and eliminates ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 2015 Une nouvelle approche ... Bremachlorin contre le cancer avancé.    ... l,immunothérapie au traitement photodynamique au Bremachlorin contre le ... Une nouvelle approche consistant à combiner l,immunothérapie au ...    Clinical Cancer Research . ...
(Date:11/27/2015)... NEW YORK , November 27, 2015 ... health system is set to go online. The potential ... and processes is vast and far from fully exploited ... access to patient health records, either via mobile tablet ... ) --> ) ...
(Date:11/27/2015)... Niederlande, November 27, 2015 ... bei fortgeschrittenem Krebs.   --> Ein ... fortgeschrittenem Krebs.   --> Ein ... fortgeschrittenem Krebs.   Clinical Cancer Research ... Clinical Cancer Research vom 6. November ...
Breaking Medicine Technology: